PIERRE FABRE CDMO Supercritical Fluids A supercritical CO2 GMP Unit for Pharmaceutical Applications.
Pierre Fabre CDMO Supercritical Fluids is a Supercritical CO2 good manufacturing practice (GMP) unit for Pharmaceutical applications, which proposes development and manufacturing services.
The company is well known as a contract manufacturer and it performs pre-formulation of active pharmaceutical ingredients (API) through patented processes Formulcoat®, Fomulplex®, and Formuldisp®.
This French manufacturing plant also performs technical transfer and cleaning of medical components by supercritical carbon dioxide technology.
Drug Delivery enhancement of API using supercritical CO2
The Supercritical Fluids department of Pierre Fabre Group began its activity in drug delivery enhancement performing pre-formulations of API using three developed patented processes.
For product requests involving changes to solubility, bioavailability, or taste-masking, Pierre Fabre contract and development manufacturing organisation (CDMO) conducts a feasibility study to ensure the customer’s needs are met. These are performed once a quotation has been approved. After evaluation and modifications have been made, a development and supply agreement can be implemented.
The company’s development workshop can treat a wide range of API, including high-potency drugs.
Active pharmaceutical ingredient taste-masking
The FORMULCOAT® process is used for the taste-masking of bitter APIs. It is an innovative patented coating process, which uses a uniform and homogeneous layer of lipidic agent without any agglomeration.
Formulcoat® is able to coat particles even less than 50µm without any use of organic solvents. The process can be applied to large batches and it occurs at room temperature.
Improving bioavailability of poorly-soluble API and making new formulations of pre-marketed API
The FORMULPLEX® process improves the bioavailability of poorly-soluble APIs. This novel patented process involves complexation with cyclodextrin in supercritical CO2.
It is considered as a first step of the formulation process by Health Authorities and helps make new formulations of already marketed API’s, generating property (life cycle management).
Formulplex® is a single step process, which is solvent-free and uses a simple and reproducible reaction.
FORMULDISP® process increases excipient functionality. This innovative, single step, patented process uses high-pressure CO2 as a medium to load an API in an excipient matrix.
The result is a totally stable solid dispersion, with enhanced properties. This process is suitable for oral administration using G.R.A.S polymer.
Scale-up of supercritical CO2 processes via a GMP unit
In addition to these Drug Delivery enhancement services, Pierre Fabre CDMO Supercritical Fluids offers to scale-up other supercritical CO2 processes in its specialised good manufacturing practice (GMP) unit.
Located in Southwest of France, the state-of-the-art unit can ensure the optimisation process and the manufacturing of clinical and commercial batches for pharmaceutical applications.
Its workshop is a multipurpose platform, which is recognised as a pharmaceutical establishment by French authorities. The facility is located in a Food and Drug Administration (FDA) inspected site and also accords to ICHQ7A guidelines.
Cleaning of medical devices
Pierre Fabre CDMO Supercritical Fluids now applies its supercritical technology to clean medical components such as gaskets used in metered-dose inhalers or medical textiles.
The process achieves efficient results, degreasing without toxic or dangerous solvents and without a drying step. Contaminants such as oils and lubes are removed, even from small cracks and crevices. Furthermore, performance and quality of the treated materials are unaffected.
The cleaning of medical components by supercritical fluids is a totally green and efficient process. Products are treated in reactors of 2-and50 litre capacity in an ISO 7 clean room.
Products and Services
Contract Manufacturing Organisation in Supercritical CO2
The company is a contract manufacturing organisation in supercritical CO2, providing cGMP clinical and commercial batches.
Pre-formulation of API by Patented Processes
The company provides Formulcoat® for taste-masking.
Custom Purification of Injectable Polymers
Pierre Fabre Médicament's supercritical division has industrialised a process to extract monomers or low molecular weight fraction from an injectable polymer.
Cleaning of Medical Devices
Pierre Fabre's supercritical (SC) fluids unit proposes its services to clean medical components by SC CO2.
Pierre Fabre Supercritical Fluids Unit Proposes its Services to Clean Medical Components by Supercritical CO²
Using supercritical CO² is an innovative and efficient way to clean and degrease.
Pierre Fabre CDM: Supercritical Fluids Expertise
Pierre Fabre Médicament - Supercritical Fluids Division is a specific department of the French independent pharmaceutical Pierre Fabre laboratories, using supercritical fluids for pharmaceutical applications.
Custom Purification of Injectable Polymers via Carbon Dioxide Dissolution
Pierre Fabre Médicament's Supercritical division has devised a smart, good manufacturing practice (GMP) compliant and industrialised process to extract monomers from injectable polymer substances.
Pierre Fabre CDMO has announced it will be presenting its innovative SuperCritical CO2 technology during CPhI US & North America 2018.Read more
Pierre Fabre will be attending CPhI Worldwide, the world's largest exhibition for global pharmaceutical ingredients, fine chemicals, and excipients in Barcelona.Read more
The Supercritical Fluids division of Pierre Fabre Medicament will attend Drug Delivery Partnerships (DDP) 2016 in Florida as an exhibitor from 21-22 January.Read more
Pierre Fabre Medicament SuperCritical Fluids Division Exhibits at Controlled Release Society (CRS) Annual Meeting
Pierre Fabre Medicament will be exhibiting at the CRS exhibition from 27-28 July 2015 at Edinburgh International Conference Centre in Scotland.Read more
Pierre Fabre Supercritical Fluids Division will be attending CPhI - ICSE Japan 2015 at Tokyo Big Sight in Tokyo, Japan.Read more
Pierre Fabre Medicament - Supercritical Fluids Division is to host a booth at the forthcoming CPhI Worldwide.Read more
‘Green Pre-Formulation Services’ with Pierre Fabre Médicament – SuperCritical Fluids Division at CPhI Japan 2013
Pierre Fabre Médicament - SuperCritical Fluids Division - will exhibit at CPhI Japan on 24 - 26 April 2013 at Big Sight Exhibition Center, Tokyo.Read more
CRS is dedicated to the delivery science and technology. This year the supercritical fluids division of Pierre Fabre Medicament will be attending this event to showcase its innovative services in pre-formulation of API.Read more
Pierre Fabre Médicament - SuperCritical Fluids Division offers pre-formulation services which permit the development of new molecules and the optimisation of the lifecycle product management.Read more
Pierre Fabre Médicament - SuperCritical Fluids Division will be an exhibitor at CPhI Japan 2012, which will be held at the Big Sight Exhibition Center in Tokyo, 21-23 March 2012.Read more
Pierre Fabre Médicament - SuperCritical Fluids Division will be an exhibitor at DDP 2012 in Las Vegas (25-27 January).Read more
Pierre Fabre Médicament - SuperCritical Fluids Division - proposes its expertise to external partners. This unit uses supercritical fluids for: Pre-formulation (coating, complexation by cyclodextrin, solid dispersion, etc.) Extraction, purification CleaningRead more
Pierre Fabre Médicament: A cGMP Supercritical Fluids Unit at AAPS Annual Meeting and Exposition in Washington DC
AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to public health. This year Pierre Fabre Médicament - Supercritical Fluids Division will once again be exhibiting at the AAPS annual meeting to present its innovative preRead more
Pierre Fabre Medicament explains the advantages of using supercritical CO2 technology for cleaning. Already well known for its pre-formulation solutions permitting the increase of bioavailability, dissolution rate, taste-masking, etc. of an API, the supercritical fluids department of PiRead more
Pierre Fabre Médicament has an extensive expertise in supercrititical fluids and has developed a new coating process called FORMULCOAT®. This process gives a performing taste-masking even for micro particles (<50µm) and thermo-sensitive particles. This process does not use any orgaRead more
Pierre Fabre Médicament - Supercritical Fluids Division, a unit of Pierre Fabre Médicament, the second independent pharmaceutical French laboratory, is pleased to announce that it will attend the following events in 2011: 26-28 January 2011: Drug Delivery Partnership (DDP) MiaRead more
From 15 to 17 November 2010, Pierre Fabre Medicament will be exhibiting at the AAPS annual meeting in the Morial Convention Centre in New Orleans, Louisiana, US. Do you have critical problems in terms of solubility, bioavailability, stabilisation, taste-masking and more? We have SuperCRead more
From 21 to 23 April 2010, Pierre Fabre Medicament will be exhibiting at CPhI Japan 2010 in Tokyo, at the Tokyo Big Sight Exhibition Centre. Interested in our extensive expertise in supercritcal fluids focused on the development of innovative API formulations? Please contact us to make aRead more
From 13-15 October 2009, Pierre Fabre Medicament will be exhibiting at CPhI Worldwide 2009 in Madrid. Interested in our extensive expertise in supercritcal fluids focused on the development of innovative API formulations? Please contact us to make an appointment for CPhI Worldwide 2009. You can aRead more
Pierre Fabre Medicament: Exhibitor at CPhI South America 2009, Sao Paulo, from 26 August to 28 August
Pierre Fabre Medicament will exhibit at CPhI South America 2009, which will be held from 26 August to 28 August in Sao Paulo's Transamerica Expo Center, Brazil. The supercritical fluids division will present its updated technologies using supercritical fluids at stand 755. PleRead more
Pierre Fabre Medicament will exhibit at Controlled Release Society 2009, which will be held from 20 July to 22 July in Copenhagen's Bella Center, Denmark. The supercriticalfluids division will present its updated technologies using supercritical fluid at stand 408.Read more
Pierre Fabre Medicament will exhibit at CPhI Japan 2009, which will be held on 21-23 April 2009 at Tokyo Big Sight Exhibition Center. Our supercritical fluids division will present its updated technologies using supercritical fluid at Pierre Fabre Medicament's stand, number D-18.Read more
Pierre Fabre Medicament will exhibit at AAPS Atlanta 2008, which will be held between the 16th and the 20th of November 2008. Our supercritical fluids division will present its updated technologies using supercritical fluid at stand Pierre Fabre Medicament, number 2637. We will also have a posteRead more
Dr Hubert Lochard, R&D Project Manager, will give a conference at Dissolution Testing, Bioavailability & Bioequivalence organised by Informa on November, 21st in Berlin. The topic of his presentation is Bioavailability Enhancement by a Supercritical Process. He will giveRead more
Based on our know-how in supercritical fluids, we have developed a multi-purpose technology platform. Today, three main technologies are available from development to commercial production: nanoparticles, FORMULPLEX® and FORMULCOAT®. NANOPARTICLES Enhancing tRead more
Pierre Fabre Medicament (active ingredients division) will be participating in the following events : Strategies to Enhance Solubility, Permeability and Absorption of Drugs, Amsterdam. December 12th and 13th Drug Delivery Partnerships, Las Vegas, NV. January, 22nd to 24Read more
Pierre Fabre Medicament - active ingredient division - has recently enlarged its Drug Delivery Technology portfolio based on its knowledge in SuperCritical Fluids. This innovative coating technology enables the coating of small-sized particles and an alternative process enablesRead more
Pierre Fabre Medicament - active ingredients division - will be attending Natural Products in Drug Discovery & Development on the 21-22 June 2006 in London. Based on 40 years' experience, Pierre Fabre Medicament is highly active in the development of plant-derived APIs. FromRead more
Pierre Fabre Medicament - active ingredients division - will be exhibiting at INFORMEX (Stand #1342) and will give two presentations on the 14th of February : 11:20 am - 11:40 am : Technology Showcase AN INNOVATIVE SOLUTION TO DEVELOP POORLY SOLUBLE APIS - BIOAVAILABILRead more
On the occasion of CPhI, Pierre Fabre Medicament, Active Ingredients Division, will present its innovative technology enabling the development of poorly-soluble APIs. PFM has developed an extensive expertise in solubility enhancement of molecules exhibiting a low bioavailability. RESS,Read more
Dramatic bioavailability increase of API in SuperCritical medium. Plantes & Industrie, development and manufacturing site of Pierre Fabre Group, has published an article in the April issue of Speciality Chemicals Magazine (http://www.specchemonline.com/). This press release providRead more
Plantes & Industrie, the development and manufacturing site of Pierre Fabre Group, has successfully launched its two new state-of-the-art development and production units. These facilities are dedicated to the industrial production of nanopowders and complexation with cyclodextrins. The mainRead more